Eli Lilly’s big investment, cheaper Zepbound, and what’s next for Hims & Hers: Pharma news roundup
Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also made a wider range of doses of its blockbuster weight-loss drug Zepbound available in vials and at lower prices. Meanwhile, Hims & Hers, which profited heavily last year from selling an off-brand…
Read more…
